文献速递心律失常心力衰竭与心肌病瓣膜病与结构性心脏病

心脏结节病相关室速导管消融的结局

Outcomes Associated With Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis.
PubMed 文献 · JAMA Cardiol · 2022-01-01

该队列研究纳入心脏结节病合并室速患者158例,评估导管消融的结局。完全手术成功率达54%,消融后室速风暴复发减少,除颤器电击显著减少。随访中46%出现室速复发,51%达到复合终点。射血分数<50%和心肌炎症与不良预后相关。

要点

  • 导管消融可使54%患者达到完全手术成功(无诱发性室速)。
  • 消融后除颤器电击中位数从2次降至0次(P<.001)。
  • 射血分数<50%和心肌炎症与不良长期预后独立相关。

核心结论

  • 在心脏结节病合并室速患者中,导管消融与除颤器电击减少和复发性室速风暴减少相关。
  • 消融前左室功能障碍和心肌炎症与不良长期预后相关。
  • 数据支持导管消融联合药物治疗用于心脏结节病相关室速的管理。

研究设计与样本

  • 这项队列研究来自心脏结节病联盟注册研究(2003-2019),包含美国、欧洲和亚洲的16个三级转诊中心。
  • 共纳入158例连续的心脏结节病合并室速患者(33%女性;平均[SD]年龄52[11]岁;53%射血分数<50%)。

主要发现

  • 完全手术成功(消融后无诱发性室速)在85例(54%)中实现。
  • 除颤器电击在消融前后30天内从中位数(IQR)2(1-5)次显著减少至0(0-0)次(P<.001)。
  • 中位(IQR)随访2.5(1.1-4.9)年期间,73例(46%)出现室速复发,81例(51%)达到复合主要终点。
  • 无室速复发、心脏移植或死亡的1年和2年生存率分别为60%和52%。

关键数值与推荐

  • 多变量分析中,射血分数<50%与主要终点不良预后显著相关(HR,2.24;95%CI,1.37-3.64;P=.001)。
  • 术前18F-氟脱氧葡萄糖正电子发射断层扫描显示心肌炎症与主要终点不良预后显著相关(HR,2.93;95%CI,1.31-6.55;P=.009)。
  • 高血压病史与有利的长期结局相关(校正HR,0.51;95%CI,0.28-0.92;P=.02)。

临床怎么用

  • 对于心脏结节病合并室速患者,可考虑导管消融联合药物治疗以减少除颤器电击和室速风暴。
  • 消融前应评估左室射血分数和心肌炎症状态,以识别长期预后不良的高危患者。

局限性

  • 这是一项观察性研究,纳入的是经过选择的心脏结节病合并室速患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Ventricular tachycardia (VT) is associated with high mortality in patients with cardiac sarcoidosis (CS), and medical management of CS-associated VT is limited by high failure rates. The role of catheter ablation has been investigated in small, single-center studies. OBJECTIVE: To investigate outcomes associated with VT ablation in patients with CS. DESIGN, SETTING, AND PARTICIPANTS: This cohort study from the Cardiac Sarcoidosis Consortium registry (2003-2019) included 16 tertiary referral centers in the US, Europe, and Asia. A total of 158 consecutive patients with CS and VT were included (33% female; mean [SD] age, 52 [11] years; 53% with ejection fraction [EF] <50%). EXPOSURES: Catheter ablation of CS-associated VT and, as appropriate, medical treatment. MAIN OUTCOMES AND MEASURES: Immediate and short-term outcomes included procedural success, elimination of VT storm, and reduction in defibrillator shocks. The primary long-term outcome was the composite of VT recurrence, heart transplant (HT), or death. RESULTS: Complete procedural success (no inducible VT postablation) was achieved in 85 patients (54%). Sixty-five patients (41%) had preablation VT storm that did not recur postablation in 53 (82%). Defibrillator shocks were significantly reduced from a median (IQR) of 2 (1-5) to 0 (0-0) in the 30 days before and after ablation (P < .001). During median (IQR) follow-up of 2.5 (1.1-4.9) years, 73 patients (46%) experienced VT recurrence and 81 (51%) experienced the composite primary outcome. One- and 2-year rates of survival free of VT recurrence, HT, or death were 60% and 52%, respectively. EF less than 50% and myocardial inflammation on preprocedural 18F-fluorodeoxyglucose positron emission tomography were significantly associated with adverse prognosis in multivariable analysis for the primary outcome (HR, 2.24; 95% CI, 1.37-3.64; P = .001 and HR, 2.93; 95% CI, 1.31-6.55; P = .009, respectively). History of hypertension was associated with a favorable long-term outcome (adjusted HR, 0.51; 95% CI, 0.28-0.92; P = .02). CONCLUSIONS AND RELEVANCE: In this observational study of selected patients with CS and VT, catheter ablation was associated with reductions in defibrillator shocks and recurrent VT storm. Preablation LV dysfunction and myocardial inflammation were associated with adverse long-term prognosis. These data support the role of catheter ablation in conjunction with medical therapy in the management of CS-associated VT.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Siontis KC, Santangeli P, Muser D, et al. Outcomes Associated With Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis. JAMA Cardiol. 2022. PMID: 34787643. doi:10.1001/jamacardio.2021.4738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。